Stockscreener 앱 받기
0.00
100.00%
-28.69
Damora Therapeutics Inc 주식(GLTO)의 최신 뉴스
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
DMRA Technical Analysis & Stock Price Forecast - Intellectia AI
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
Will Widening Net Losses And New Finance Chief Change Damora Therapeutics' (DMRA) Narrative - Sahm
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Forecast and Price Target 2026 - MarketBeat
Point72-backed entities report 1.19M shares in Damora (DMRA) - Stock Titan
Damora Therapeutics (DMRA) filing: Jain Global group reports 0.0% stake - Stock Titan
Avoro Capital (DMRA) and Dr. Aghazadeh report 3.78M shares (6.27%) - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Financials 2026Income Statement and Balance Sheet - MarketBeat
Damora Therapeutics, Inc. Stock 12‑Month Price Target Cut to $44.5, Implies 93% Upside - TradingView
Damora's $533M Gambit: New Leadership Targets Rare Blood Cancers - BriefGlance
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Therapeutics 1Q 2026: Net loss $27.8M — 10-Q Summary - TradingView
Damora funds 3 blood-disorder drugs with $533M cash into 2029 - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Damora Therapeutics (DMRA) ramps mutCALR R&D with major cash raise - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated May 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Number of shareholders of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders - Yahoo Finance
Damora Therapeutics (DMRA) SVP reports 312,535-share stock option grant - Stock Titan
A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals - Sahm
Damora Therapeutics Appoints Jennifer Jarrett as New Chief Executive - HarianBasis.co
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer - Yahoo Finance
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum - Yahoo Finance
Damora Therapeutics Announces CFO Transition to Internal Leader - TipRanks
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Damora Therapeutics: Lori Firmani to cease serving as CFO effective May 1, 2026SEC filing - marketscreener.com
Damora Therapeutics (NASDAQ: DMRA) replaces CFO, elevating SVP finance - Stock Titan
2.98%
1.33%
자본화:
|
볼륨(24시간):